Antiplatelet drug resistance: Not ready for prime time

Research output: Contribution to journalShort survey

7 Citations (Scopus)

Abstract

Antiplatelet drug therapy reduces vascular events in a wide range of patients. Although antiplatelet drug resistance is becoming well documented, a universal definition has not been established. This lack and the lack of standardized measures of platelet function make estimation of the prevalence of antiplatelet drug resistance difficult. Mounting evidence suggests that antiplatelet drug resistance is associated with adverse clinical outcomes, which have been assessed in patients with coronary artery disease, myocardial infarction, cerebrovascular disease, and peripheral vascular disease. Patients with antiplatelet drug resistance have significantly more vascular events than patients without such resistance. However, there are no guidelines for the treatment of antiplatelet drug resistance. Although point-of-care platelet-function testing makes screening for resistance feasible, routine screening should not be standard practice until data regarding the management of antiplatelet drug resistance are available.

Original languageEnglish
Pages (from-to)1621-1628
Number of pages8
JournalPharmacotherapy
Volume25
Issue number11 I
DOIs
StatePublished - Nov 2005

Fingerprint

Platelet Aggregation Inhibitors
Drug Resistance
Blood Vessels
Blood Platelets
Point-of-Care Systems
Cerebrovascular Disorders
Peripheral Vascular Diseases
Guidelines
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Antiplatelet drug resistance : Not ready for prime time. / Burns, Tammy L.; Mooss, Aryan N.; Hilleman, Daniel E.

In: Pharmacotherapy, Vol. 25, No. 11 I, 11.2005, p. 1621-1628.

Research output: Contribution to journalShort survey

@article{c19453475f6f4fdf8d01466ab809a900,
title = "Antiplatelet drug resistance: Not ready for prime time",
abstract = "Antiplatelet drug therapy reduces vascular events in a wide range of patients. Although antiplatelet drug resistance is becoming well documented, a universal definition has not been established. This lack and the lack of standardized measures of platelet function make estimation of the prevalence of antiplatelet drug resistance difficult. Mounting evidence suggests that antiplatelet drug resistance is associated with adverse clinical outcomes, which have been assessed in patients with coronary artery disease, myocardial infarction, cerebrovascular disease, and peripheral vascular disease. Patients with antiplatelet drug resistance have significantly more vascular events than patients without such resistance. However, there are no guidelines for the treatment of antiplatelet drug resistance. Although point-of-care platelet-function testing makes screening for resistance feasible, routine screening should not be standard practice until data regarding the management of antiplatelet drug resistance are available.",
author = "Burns, {Tammy L.} and Mooss, {Aryan N.} and Hilleman, {Daniel E.}",
year = "2005",
month = "11",
doi = "10.1592/phco.2005.25.11.1621",
language = "English",
volume = "25",
pages = "1621--1628",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "11 I",

}

TY - JOUR

T1 - Antiplatelet drug resistance

T2 - Not ready for prime time

AU - Burns, Tammy L.

AU - Mooss, Aryan N.

AU - Hilleman, Daniel E.

PY - 2005/11

Y1 - 2005/11

N2 - Antiplatelet drug therapy reduces vascular events in a wide range of patients. Although antiplatelet drug resistance is becoming well documented, a universal definition has not been established. This lack and the lack of standardized measures of platelet function make estimation of the prevalence of antiplatelet drug resistance difficult. Mounting evidence suggests that antiplatelet drug resistance is associated with adverse clinical outcomes, which have been assessed in patients with coronary artery disease, myocardial infarction, cerebrovascular disease, and peripheral vascular disease. Patients with antiplatelet drug resistance have significantly more vascular events than patients without such resistance. However, there are no guidelines for the treatment of antiplatelet drug resistance. Although point-of-care platelet-function testing makes screening for resistance feasible, routine screening should not be standard practice until data regarding the management of antiplatelet drug resistance are available.

AB - Antiplatelet drug therapy reduces vascular events in a wide range of patients. Although antiplatelet drug resistance is becoming well documented, a universal definition has not been established. This lack and the lack of standardized measures of platelet function make estimation of the prevalence of antiplatelet drug resistance difficult. Mounting evidence suggests that antiplatelet drug resistance is associated with adverse clinical outcomes, which have been assessed in patients with coronary artery disease, myocardial infarction, cerebrovascular disease, and peripheral vascular disease. Patients with antiplatelet drug resistance have significantly more vascular events than patients without such resistance. However, there are no guidelines for the treatment of antiplatelet drug resistance. Although point-of-care platelet-function testing makes screening for resistance feasible, routine screening should not be standard practice until data regarding the management of antiplatelet drug resistance are available.

UR - http://www.scopus.com/inward/record.url?scp=27644559048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644559048&partnerID=8YFLogxK

U2 - 10.1592/phco.2005.25.11.1621

DO - 10.1592/phco.2005.25.11.1621

M3 - Short survey

C2 - 16232023

AN - SCOPUS:27644559048

VL - 25

SP - 1621

EP - 1628

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 11 I

ER -